GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LUMOSA THERAPEUTICS CO LTD (ROCO:6535) » Definitions » Cyclically Adjusted Price-to-FCF

LUMOSA THERAPEUTICS CO (ROCO:6535) Cyclically Adjusted Price-to-FCF : (As of Jun. 19, 2024)


View and export this data going back to 2015. Start your Free Trial

What is LUMOSA THERAPEUTICS CO Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


LUMOSA THERAPEUTICS CO Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for LUMOSA THERAPEUTICS CO's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LUMOSA THERAPEUTICS CO Cyclically Adjusted Price-to-FCF Chart

LUMOSA THERAPEUTICS CO Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

LUMOSA THERAPEUTICS CO Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of LUMOSA THERAPEUTICS CO's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, LUMOSA THERAPEUTICS CO's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LUMOSA THERAPEUTICS CO's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LUMOSA THERAPEUTICS CO's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where LUMOSA THERAPEUTICS CO's Cyclically Adjusted Price-to-FCF falls into.



LUMOSA THERAPEUTICS CO Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

LUMOSA THERAPEUTICS CO's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, LUMOSA THERAPEUTICS CO's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.491/131.7762*131.7762
=-0.491

Current CPI (Mar. 2024) = 131.7762.

LUMOSA THERAPEUTICS CO Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 0.000 98.326 0.000
201406 0.000 100.560 0.000
201412 0.000 99.070 0.000
201503 -0.457 99.621 -0.605
201506 -0.519 100.684 -0.679
201509 -0.657 100.392 -0.862
201512 -0.124 99.792 -0.164
201603 -0.443 100.470 -0.581
201606 -0.574 101.688 -0.744
201609 -0.060 101.861 -0.078
201612 -0.596 101.863 -0.771
201703 -0.320 102.862 -0.410
201706 -0.058 103.349 -0.074
201709 -0.272 104.136 -0.344
201712 -0.089 104.011 -0.113
201803 -0.397 105.290 -0.497
201806 -0.242 106.317 -0.300
201809 -0.306 106.507 -0.379
201812 0.027 105.998 0.034
201903 -0.306 107.251 -0.376
201906 -0.454 108.070 -0.554
201909 -0.596 108.329 -0.725
201912 -1.880 108.420 -2.285
202003 1.248 108.902 1.510
202006 -0.791 108.767 -0.958
202009 -0.848 109.815 -1.018
202012 -0.641 109.897 -0.769
202103 -0.609 111.754 -0.718
202106 -0.690 114.631 -0.793
202109 -0.541 115.734 -0.616
202112 -1.153 117.630 -1.292
202203 -0.457 121.301 -0.496
202206 -0.543 125.017 -0.572
202209 -0.604 125.227 -0.636
202212 -0.244 125.222 -0.257
202303 -0.475 127.348 -0.492
202306 -0.682 128.729 -0.698
202309 -0.400 129.860 -0.406
202312 -0.458 129.419 -0.466
202403 -0.491 131.776 -0.491

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


LUMOSA THERAPEUTICS CO  (ROCO:6535) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


LUMOSA THERAPEUTICS CO Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of LUMOSA THERAPEUTICS CO's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


LUMOSA THERAPEUTICS CO (ROCO:6535) Business Description

Traded in Other Exchanges
N/A
Address
Yuanyuan Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503
LUMOSA THERAPEUTICS CO LTD develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of CNS, oncology, and inflammatory diseases. Geographically, it derives a majority of its revenue from Asia and also has a presence in Taiwan and America. Its product portfolio includes LT - 1001 and LT - 3001 for Analgesic Injection and Novel Small Molecules for the Treatment of Acute Ischemic Stroke.

LUMOSA THERAPEUTICS CO (ROCO:6535) Headlines

No Headlines